• Home
  •  / Vertex Pharmaceuticals

Vertex Pharmaceuticals

OverviewSuggest Edit

Vertex Pharmaceuticals is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases and cancer.
TypePublic
Founded1989
HQBoston, MA, USMap
Websitevrtx.com
Employee Ratings3.6More
Overall CultureA+More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)3,000(+20%)
Revenue (FY, 2020)$6.2 B(+50%)
Share Price (Mar 2021)$210.4 (-1%)
Cybersecurity ratingDMore

Key People/Management at Vertex Pharmaceuticals

Jeffrey Leiden

Jeffrey Leiden

Executive Chairman
Reshma Kewalramani

Reshma Kewalramani

Chief Executive Officer, President & Director
Sangeeta N. Bhatia

Sangeeta N. Bhatia

Director
David Altshuler

David Altshuler

Executive Vice President, Global Research and Chief Scientific Officer
Carmen Bozic

Carmen Bozic

Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer
Stuart A. Arbuckle

Stuart A. Arbuckle

Executive Vice President and Chief Commercial Officer
Show more

Vertex Pharmaceuticals Office Locations

Vertex Pharmaceuticals has offices in Boston, San Diego, Washington, Watertown and in 18 other locations
Boston, MA, US (HQ)
50 Northern Ave
San Diego, CA, US
3215 Merryfield Row
Washington, DC, US
1050 K St NW
Watertown, MA, US
490 Arsenal Way #110
St Leonards, AU
level 3 suite 3/601 Pacific Hwy
Wien, AT
Lehrbachgasse 13
Show all (27)

Vertex Pharmaceuticals Financials and Metrics

Vertex Pharmaceuticals Revenue

Vertex Pharmaceuticals's revenue was reported to be $6.21 b in FY, 2020
USD

Revenue (FY, 2020)

6.2b

Gross profit (FY, 2020)

5.5b

Gross profit margin (FY, 2020), %

88.1%

Net income (FY, 2020)

2.7b

EBIT (FY, 2020)

2.9b

Market capitalization (1-Mar-2021)

54.7b

Closing stock price (1-Mar-2021)

210.4

Cash (31-Dec-2020)

6.0b

EV

49.6b
Vertex Pharmaceuticals's current market capitalization is $54.7 b.
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

143.4m1.4b1.5b1.2b580.4m1.0b1.7b2.5b3.0b4.2b6.2b

Revenue growth, %

(52%)78%65%

Cost of goods sold

63.6m236.7m89.0m39.7m117.2m206.8m272.7m409.5m547.8m736.3m

Gross profit

1.3b1.3b1.1b540.7m915.2m1.5b2.2b2.6b3.6b5.5b
Quarterly
USDQ1, 2010Q2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

22.4m31.6m23.8m73.7m114.4m659.2m438.7m418.3m336.0m328.4m310.8m221.7m118.5m138.4m179.0m138.5m166.1m309.8m398.1m431.6m413.8m714.7m544.1m578.2m640.8m752.2m784.5m858.4m941.3m949.8m1.5b1.5b1.5b

Cost of goods sold

5.4m35.3m25.9m104.5m30.7m31.0m24.7m20.0m8.6m9.7m10.2m9.4m15.4m30.3m49.8m44.2m53.2m46.2m70.5m72.2m71.6m104.4m111.3m95.1m135.7m131.9m162.5m

Gross profit

109.0m623.9m412.8m313.8m305.3m297.4m286.1m201.7m109.9m128.8m168.8m129.1m150.7m279.5m348.3m387.5m360.6m668.5m473.6m506.0m569.2m647.8m673.3m763.3m805.6m817.9m1.4b

Gross profit Margin, %

95%95%94%75%91%91%92%91%93%93%94%93%91%90%87%90%87%94%87%88%89%86%86%89%86%86%89%
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

243.2m475.3m489.4m569.3m625.3m714.8m1.2b1.7b2.7b3.1b6.0b

Accounts Receivable

12.5m183.1m143.3m85.5m76.0m177.6m201.1m281.3m409.7m633.5m885.4m

Prepaid Expenses

14.9m24.7m23.8m52.6m50.9m165.6m140.8m213.5m308.4m

Inventories

112.4m30.5m14.1m30.8m57.2m77.6m111.8m124.4m167.5m280.8m
Quarterly
USDQ1, 2010Q2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

396.5m337.6m569.9m446.5m458.2m542.5m267.9m454.1m436.9m379.1m531.2m583.2m424.0m420.6m718.6m664.9m870.5m756.3m604.2m605.9m719.7m1.0b1.2b1.4b2.0b2.1b2.5b2.9b3.3b3.4b3.6b4.8b5.4b

Accounts Receivable

7.9m3.5m5.0m5.6m96.0m445.7m232.2m185.6m139.6m194.1m164.9m120.3m59.9m81.8m114.3m80.3m94.5m165.3m181.9m189.4m182.2m208.0m247.9m263.5m327.3m393.4m379.8m438.3m464.9m443.3m845.3m791.8m791.9m

Prepaid Expenses

23.2m35.4m40.5m35.1m47.8m43.2m41.1m35.0m34.4m41.3m62.6m53.3m63.4m55.9m56.3m61.0m128.5m107.1m152.2m109.9m122.7m118.7m130.0m151.8m175.1m223.6m232.6m270.0m

Inventories

17.8m52.6m67.7m129.6m87.8m86.3m21.5m19.5m13.5m11.3m12.0m16.8m34.1m42.1m49.2m63.2m66.6m71.8m82.0m92.3m98.2m117.3m115.0m124.2m136.7m143.0m162.3m187.1m219.2m245.5m
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(754.6m)29.6m(107.0m)(687.5m)(742.7m)(588.2m)(84.0m)91.6m2.1b1.2b2.7b

Depreciation and Amortization

30.5m35.0m38.2m48.4m63.3m62.3m61.4m61.4m72.4m106.9m109.5m

Inventories

(111.4m)(29.9m)7.1m(16.5m)(23.1m)(16.4m)(45.0m)(32.0m)(64.0m)(132.0m)

Accounts Payable

(1.2m)37.5m14.9m(49.2m)25.0m(1.7m)(11.7m)8.8m36.6m(22.8m)51.3m
Quarterly
USDQ1, 2010Q2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(165.3m)(365.3m)(574.2m)(176.1m)(350.2m)(129.1m)91.6m26.7m(30.9m)(308.0m)(57.2m)(124.1m)(232.5m)(391.8m)(561.9m)(198.7m)(419.7m)(513.5m)(36.1m)(72.3m)(111.8m)249.5m280.7m(10.5m)227.3m433.6m562.0m268.6m536.1m593.6m602.8m1.4b2.1b

Depreciation and Amortization

7.6m15.5m22.3m8.9m17.6m25.3m8.6m17.2m25.8m10.7m15.8m30.0m46.9m16.4m30.4m46.6m16.4m31.4m45.9m14.9m29.7m45.0m16.3m34.4m53.6m27.1m54.8m80.7m26.8m53.5m80.2m

Inventories

(17.7m)(52.1m)(66.8m)(16.9m)(34.3m)(32.4m)9.2m2.5m1.2m(4.9m)(2.6m)(9.4m)(16.1m)(4.8m)(7.8m)(11.5m)(3.6m)(22.0m)(28.6m)(8.2m)(9.4m)(24.5m)(13.1m)(25.2m)(45.3m)(27.4m)(64.4m)(94.9m)

Accounts Payable

(8.0m)9.6m(12.3m)(1.1m)30.1m12.1m(1.4m)(15.3m)1.4m(40.6m)978.0k7.7m(5.5m)(23.6m)(3.0m)6.3m(343.0k)(23.8m)(21.5m)717.0k14.0m6.9m2.2m12.2m23.0m(24.1m)(28.1m)(12.2m)14.3m14.7m16.2m
show all
USDQ1, 2010

Financial Leverage

1.8 x
Show all financial metrics

Vertex Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
Semma TherapeuticsSeptember 03, 2019$950 m

Vertex Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

D

65/100

Learn more about our premium products
SecurityScorecard logo

Vertex Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

Learn more about our premium products
CSRHub logo

Vertex Pharmaceuticals Online and Social Media Presence

Vertex Pharmaceuticals's Trends

Embed Graph

Vertex Pharmaceuticals Company Culture

  • Overall Culture

    A+

    92/100

  • CEO Rating

    A+

    85/100

  • Compensation

    A+

    95/100

  • Diversity

    A+

    91/100

Learn more on Comparably

Vertex Pharmaceuticals Blogs

February 24, 2021

Vertex to Present at the Cowen Health Care Conference on March 2

BOSTON --(BUSINESS WIRE)--Feb. 24, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 2, 2021 at 9:50 a.m. ET . The audio portion of management's remarks will be available live through Vertex
February 01, 2021

Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results

-Full-year 2020 GAAP product revenues of $6.20 billion - -Full-year 2020 non-GAAP product revenues of $6.20 billion , a 55% increase compared to full-year 2019- -Company provides full-year 2021 product revenue guidance of $6.7 to $6.9 billion - BOSTON --(BUSINESS WIRE)--Feb.
January 28, 2021

Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)

- Vertex will initiate a Phase 1/2 clinical trial in first half of 2021 - - VX-880 is the first stem cell-derived therapy evaluating fully differentiated pancreatic islet cells for the treatment of T1D - BOSTON --(BUSINESS WIRE)--Jan. 28, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)
January 26, 2021

Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations

Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations Content Import Tue, 01/26/2021 - 08:32 Vertex Announces U.S. FDA Acceptance of …
January 22, 2021

Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1

Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1 Content Import Fri, 01/22/2021 - 09:02 Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1 Jan 22, 2021 This release is a backfill from a News Wire W…
January 07, 2021

Vertex to Present at the J.P. Morgan Healthcare Conference on January 11

Vertex to Present at the J.P. Morgan Healthcare Conference on January 11 Content Import Thu, 01/07/2021 - 09:02 Vertex to Present at the J.P. Morgan Healthcare Conference on January 11 Jan 7, 2021 This release is a backfill from a News Wire …
Show more

 Vertex Pharmaceuticals Frequently Asked Questions

  • When was Vertex Pharmaceuticals founded?

    Vertex Pharmaceuticals was founded in 1989.

  • Who are Vertex Pharmaceuticals key executives?

    Vertex Pharmaceuticals's key executives are Jeffrey Leiden, Reshma Kewalramani and Sangeeta N. Bhatia.

  • How many employees does Vertex Pharmaceuticals have?

    Vertex Pharmaceuticals has 3,000 employees.

  • What is Vertex Pharmaceuticals revenue?

    Latest Vertex Pharmaceuticals annual revenue is $6.2 b.

  • What is Vertex Pharmaceuticals revenue per employee?

    Latest Vertex Pharmaceuticals revenue per employee is $2.1 m.

  • Who are Vertex Pharmaceuticals competitors?

    Competitors of Vertex Pharmaceuticals include Amphastar Pharmaceuticals, Biogen and Otonomy.

  • Where is Vertex Pharmaceuticals headquarters?

    Vertex Pharmaceuticals headquarters is located at 50 Northern Ave, Boston.

  • Where are Vertex Pharmaceuticals offices?

    Vertex Pharmaceuticals has offices in Boston, San Diego, Washington, Watertown and in 18 other locations.

  • How many offices does Vertex Pharmaceuticals have?

    Vertex Pharmaceuticals has 27 offices.